Ropes & Gray represented Bain Capital in connection with DRI Healthcare Trust’s acquisition of certain royalty participation rights in U.S. net sales of tavapadon, a Parkinson’s disease drug candidate, for $316 million, payable upon U.S. Food and Drug Administration approval. The deal was announced on September 21. DRI Healthcare is acquiring the royalty participation rights from funds managed by Bain Capital and NovaQuest Capital Management, which sold its interests to DRI Healthcare alongside Bain Capital.
Tavapadon is a once-daily, oral, selective dopamine receptor partial agonist for Parkinson’s disease, with approval expected in 2026.
The Ropes & Gray team was led by life sciences licensing partner Abby Gregor and life sciences counsel Michael Spera, and included private equity partner Milap Patel and tax partner Pamela Glazier.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.